Literature DB >> 9788779

[Phe1psi(CH2-NH)Gly2]nociceptin-(1-13)-NH2 acts as an agonist of the orphanin FQ/nociceptin receptor in vivo.

J E Grisel1, D E Farrier, S G Wilson, J S Mogil.   

Abstract

The orphanin FQ/nociceptin (OFQ/N) derivative peptide, [Phe1psi(CH2-NH)Gly2] nociceptin-(1-13)-NH2 (Phe(psi)), has been claimed to be both an antagonist and an agonist of the orphan opioid receptor (ORL1) in different in vitro assays. We now report the dose-dependent inhibition of morphine analgesia by Phe(psi) in mice, an effect parallel to that of OFQ/N. Further, the anti-opioid actions of OFQ/N are not blocked by Phe(psi). Thus, Phe(psi) acts as an ORL1 receptor agonist, not an antagonist, in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788779     DOI: 10.1016/s0014-2999(98)00567-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Characterization of the ORL(1) receptor on adrenergic nerves in the rat anococcygeus muscle.

Authors:  M Ho; A D Corbett; A T McKnight
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 2.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 3.  Central N/OFQ-NOP Receptor System in Pain Modulation.

Authors:  Norikazu Kiguchi; Huiping Ding; Mei-Chuan Ko
Journal:  Adv Pharmacol       Date:  2015-12-17

4.  Nociceptin, Phe(1)psi-nociceptin(1 - 13), nocistatin and prepronociceptin(154 - 181) effects on calcium channel currents and a potassium current in rat locus coeruleus in vitro.

Authors:  M Connor; C W Vaughan; E A Jennings; R G Allen; M J Christie
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

5.  [Phe1psi(CH2-NH)Gly2]nociceptin-(1 - 13)-NH2 activation of an inward rectifier as a partial agonist of ORL1 receptors in rat periaqueductal gray.

Authors:  L C Chiou
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

6.  Pharmacological profiles of a novel opioid receptor-like1 (ORL(1)) receptor antagonist, JTC-801.

Authors:  Hideki Yamada; Hiromitsu Nakamoto; Yasunori Suzuki; Takao Ito; Kazuo Aisaka
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

7.  Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors.

Authors:  N Zaveri; W E Polgar; C M Olsen; A B Kelson; P Grundt; J W Lewis; L Toll
Journal:  Eur J Pharmacol       Date:  2001-09-28       Impact factor: 4.432

8.  Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system.

Authors:  J McDonald; T A Barnes; H Okawa; J Williams; G Calo'; D J Rowbotham; D G Lambert
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

Review 9.  Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents.

Authors:  Nurulain Zaveri
Journal:  Life Sci       Date:  2003-06-27       Impact factor: 5.037

10.  Activities of mixed NOP and mu-opioid receptor ligands.

Authors:  B Spagnolo; G Calo; W E Polgar; F Jiang; C M Olsen; I Berzetei-Gurske; T V Khroyan; S M Husbands; J W Lewis; L Toll; N T Zaveri
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.